Educational content only. The following article is based on published scientific research and is provided for informational purposes. It does not constitute medical advice, diagnosis, or a treatment recommendation. Individual responses to any therapy vary. All peptide protocols at Irvine Health are available only after a licensed physician video consultation and a written prescription.
Tirzepatide is a novel once-weekly injectable peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual-receptor activity distinguishes it from single-mechanism GLP-1 agonists and has been associated with greater reductions in body weight and glycated hemoglobin in clinical trials. It was originally approved by the FDA in 2022 for type 2 diabetes management and subsequently received approval for chronic weight management in adults with obesity in 2023.
What the Research Shows
In 2,539 adults with obesity (no diabetes), tirzepatide at 5, 10, and 15 mg doses produced mean weight reductions of 15.0%, 19.5%, and 20.9% respectively from baseline over 72 weeks, versus 3.1% with placebo. At 15 mg, 57% of participants achieved ≥20% body weight reduction — a threshold that was rarely seen with single-mechanism therapies.
In adults with type 2 diabetes and obesity or overweight, tirzepatide 10 mg and 15 mg produced mean weight losses of 13.4% and 15.7% respectively versus 3.3% with placebo. Glycated hemoglobin reductions were also clinically significant across both doses.
A dedicated cardiovascular outcomes trial (SURPASS-CVOT) is underway to characterize tirzepatide's effect on major adverse cardiovascular events, following the precedent set by semaglutide's SELECT trial. Interim safety data have not raised cardiovascular concerns.
GIP Receptor: A Different Angle
GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone secreted by the small intestine in response to food. While earlier research suggested GIP receptor agonism might be counterproductive in obesity, tirzepatide's clinical results suggest that combined GIP/GLP-1 receptor activation may be synergistic — possibly by enhancing the sensitivity of adipose tissue to GLP-1 effects and improving the metabolic response in a way that single-agonist therapy does not replicate.
Areas of Clinical Research
- Chronic weight management in adults with BMI ≥30 or ≥27 with comorbidity
- Type 2 diabetes glycemic control
- Non-alcoholic fatty liver disease (NAFLD/NASH) — under active investigation
- Obstructive sleep apnea — SURMOUNT-OSA trial results published 2024 showing significant AHI reduction
- Cardiovascular risk reduction — outcomes trial ongoing
Tolerability
Like other incretin-based therapies, gastrointestinal side effects — nausea, vomiting, diarrhea — are the most commonly reported, predominantly during dose escalation. The structured escalation protocol (2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg over months) helps most patients tolerate increasing doses over time. Prescribing providers review contraindications including personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
- Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
- Dahl D, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5). JAMA. 2022;327(6):534-545.
- FDA. Highlights of Prescribing Information: Zepbound (tirzepatide) injection. 2023.